Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 28th Annual Milken Institute Global Conference on a panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs.” The Conference will take place May 4-7, 2025, at the Beverly Hilton in Los Angeles, and the panel will be held on Monday, May 5, 2025, at 2:30 p.m. PDT.
“It’s truly an honor to return to the Milken Global Conference and to contribute to the discourse around the opportunities we have as drug developers today,” stated Doug Drysdale, Cybin’s Chief Executive Officer. “These are times of extraordinary scientific innovation. We are pushing the boundaries beyond existing standards of care and offering more precise treatment regimens than ever before. As the pace of medical breakthroughs accelerates, Cybin is proud to participate in this extremely important conversation.”
The live panel discussion and archived webcast will be available on the Company’s investor relations website on the Events & Presentations page. For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org.
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.